CN101468053A - Pharmaceutical composition containing notoginseng and ginseng as well as preparation and application thereof - Google Patents
Pharmaceutical composition containing notoginseng and ginseng as well as preparation and application thereof Download PDFInfo
- Publication number
- CN101468053A CN101468053A CNA2007103038602A CN200710303860A CN101468053A CN 101468053 A CN101468053 A CN 101468053A CN A2007103038602 A CNA2007103038602 A CN A2007103038602A CN 200710303860 A CN200710303860 A CN 200710303860A CN 101468053 A CN101468053 A CN 101468053A
- Authority
- CN
- China
- Prior art keywords
- preparation
- radix ginseng
- radix notoginseng
- ethanol
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine combination containing notoginseng and ginseng and preparation method and use thereof. The injection combination for treating tumour disease is composed of effective ingredient of notoginseng and ginseng and pharmaceutic adjuvant based on Chinese medicine theory. The pharmacological results show that the combination has better pharmacological effects in the treatment of tumor diseases.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicine pharmacy, be specifically related to a kind of Radix Notoginseng, Radix Ginseng extract pharmaceutical composition and preparation method of containing, and the application of this pharmaceutical composition in the preparation antitumor drug, preparation of the present invention claims compound recipe Radix Notoginseng ejection preparation again.
Background technology
Cardiovascular and cerebrovascular disease belongs to stasis of blood disease in the traditional Chinese medical science, and blood is capable because of gas, and the stagnation of QI is blood stasis then.Therefore, treatment blood system disease must consider that edema caused by disorder of QI levies the marquis, and it is capable with short blood to regulate the flow of vital energy, and it is unobstructed that QI and blood is turned round, and is the rule of treatment for the treatment of the blood system disease.Clinical practice shows, QI invigorating is applied in a flexible way with invigorating blood circulation, and the treatment that is used for cardiovascular and cerebrovascular disease has better curative effect.
Radix Notoginseng is the dry root of panax araliaceae plant Panax notoginseng (Burk.) F.H.Chen, sweet, the little hardship of property, and temperature is returned liver, stomach warp, have the dissipating blood stasis hemostasis, the effect of subduing swelling and relieving pain is used for spitting of blood, spit blood, epistaxis is had blood in stool, metrorrhagia, traumatic hemorrhage, breast ventral spine pain, tumbling and swelling, compound components of panax notoginseng is a Radix Notoginseng total arasaponins, modern pharmacological research shows, Radix Notoginseng total arasaponins has blood vessel dilating, the effect of bringing high blood pressure down, can coronary blood flow increasing, reduce pharmacological actions such as myocardial oxygen consumption; Radix Ginseng is the dry root of Araliaceae Radix Ginseng Panax ginseng C.A.Mey., property is sweet, little hardship, flat, return spleen, lung, heart channel, has strongly invigorating primordial QI, multiple arteries and veins takes off admittedly, invigorating the spleen to benefit the lung, promote the production of body fluid, the effect of calming the nerves, Radix Ginseng contains Radix Ginseng total saponins, modern pharmacological research shows, Radix Ginseng total saponins is to rat myocardial cell calcium channel blocking action (preclinical medicine and clinical, 1994,02), single calcium channel analysis and the research of ESR spectrum (preclinical medicine and clinical, 1994 to the rat heart muscle effect, 04), Radix Ginseng total saponins is to myocardial ischemia-reperfusion dog CO, influence (Norman Bethune Medical University's journal 1995,05 of TPVR and serum N E content.), Radix Ginseng total saponins is to the protective effect of pallasiomy acute cerebral ischemia-reperfusion injury (Chinese Pharmacological circular, 1996,06), the Radix Ginseng total saponins influence pharmacological actions such as (Chinese Chinese medicine science and technology 200403) to cleft lip blood reperfusion injury cardiac hemodynamic.
Consult patent documentation, do not retrieve with Radix Ginseng, Radix Notoginseng and carry out prescription.
Summary of the invention
For these reasons, the present invention in conjunction with the clinical practice experience, dispels when becoming silted up under Chinese medical theory instructs, and notes the conditioning of edema caused by disorder of QI, makes battalion defend mediation.Side's Radix Ginseng, Radix Notoginseng, adopt the modern pharmaceutical technology to extract purification Radix Ginseng effective site ginsenoside and Sanchi effective-component Radix Notoginseng total arasaponins, be mixed with into treatment cardiovascular and cerebrovascular disease ejection preparation with pharmaceutic adjuvant, can play and in removing blood stasis, remove the tissue regeneration promoting that becomes silted up, strengthen patient's body constitution, reinforcing body resistance reaches and invigorates blood circulation and not random blood, QI invigorating and do not help the purpose of heresy.
The present invention is achieved by the following scheme.
A kind of pharmaceutical composition that contains Radix Notoginseng, Radix Ginseng is characterized in that this pharmaceutical composition is by Radix Notoginseng 1-3 weight portions, and Radix Ginseng 1-2 weight portions are formed.
Preparation of pharmaceutical compositions method: get Radix Notoginseng, Radix Ginseng, pulverize, put into the Chinese medicine multi-function extractor, added 6-10 times of water extraction 1-3 hours, and extracted 2-5 times, extracting solution filters and merges, filter, the ratio that filtrate is concentrated into medical material and medicinal liquid is 1:1, leaves standstill, centrifugal, obtain supernatant, supernatant adds ethanol, making solution contain the alcohol amount is 50%-80%, leaves standstill 24-36 hours, and supernatant reclaims ethanol to most, it is standby to obtain concentrated solution, the precipitation drying for standby; Getting macroporous adsorptive resins on the above-mentioned concentrated solution, wash with distillation earlier, is 3-5 times of column volume with distilled water, water liquid discards, and reuse 55%-75% ethanol elution, eluting ethanol are 2-6 times of column volume, eluent reclaims ethanol to most, and dry, pulverizing is standby; Get above-mentioned drying precipitated, be dissolved in water fully, with 0.1 μ m filter element filtering, filtrate is that 8000-10000 hollow fiber column carries out ultrafiltration with the intercepting molecular weight, and each ultrafiltration is during to original volume 1/2-1/3, add water to original volume, ultrafiltration 3-5 times is concentrated to pol when being 1%-4%, drying for the last time, add the dry thing of macroporous adsorptive resins ethanol elution, obtain Radix Notoginseng, Radix Ginseng extract.
The preparation of preparation of pharmaceutical compositions the treatment tumor disease aspect in application.
Said method obtains Radix Notoginseng, Radix Ginseng extract is prepared into acceptable pharmaceutical preparation on the pharmaceutics, comprise preparations such as tablet, capsule, soft capsule, granule, drop pill, oral liquid, aqueous injection, infusion solution, injectable powder,
One, check and analysis
According to high effective liquid chromatography for measuring
Chromatographic condition and system suitability test: with octadecylsilane chemically bonded silica is filler; Acetonitrile 0.05% phosphoric acid solution (19: 81) is a mobile phase; The detection wavelength is 203nm.Number of theoretical plate is by the Ginsenoside Rb
1The note peak calculates, and should be not less than 4000.
The preparation of reference substance solution: precision takes by weighing the Ginsenoside Rb who is dried to constant weight in phosphorus pentoxide desiccator
15mg puts in the 25ml measuring bottle, adds acetonitrile: water (19: 81) shakes up to scale, and precision is measured 5ml, puts in the 10ml measuring bottle, adds acetonitrile: water (19: 81) is diluted to scale, shakes up, promptly.
The preparation of need testing solution: get preparation methanol extraction of the present invention, extracting solution recovery methanol is extremely most, drying, and residue 10mg decided in accurate title, uses the mobile phase standardize solution in the 25ml volumetric flask, as need testing solution.
Algoscopy: accurate respectively reference substance solution and each 20 μ l of need testing solution of drawing, inject chromatograph of liquid respectively, measure, through calculating, the results are shown in Table 1.
Table 1 preparation active constituent content measuring of the present invention
Conclusion: show that by above check and analysis experiment technology of the present invention has practical significance.
Two, pharmacology embodiment
Embodiment 1
To the protective effect of qi-deficiency type Cor Canitis myocardial ischemia
Laboratory animal: Beagle Canis familiaris L., body weight 7.5-10kg.(causing model of qi-asthenia according to document) by herbal pharmacology teaching and research room of Shenyang Pharmaceutical University
Experiment medicine: XUESAITONG ZHUSHEYE (Kunming Medicine Group Stock Co., Ltd)
Pharmaceutical composition of the present invention
Experimental technique: get experimental dogs, be divided into the normal saline group, the XUESAITONG ZHUSHEYE group, water pharmaceutical composition group of the present invention, the administration group is respectively in the subcutaneous cephalic vein administration of Canis familiaris L. forelimb, the each 11mg effective site/kg of dosage, normal saline groups etc. are held inequality, administration every day 1 time, successive administration 3 days, pentobarbital sodium 25mg/kg intravenous anesthesia is used in administration after the 3rd day, tracheal intubation connects artificial respirator positive pressure respiration in addition, and the 5th rib is opened breast from the left side, cut off pericardium, expose heart, the pericardial incision edge is sewn in thoracic wall, divide the second stage of ligation at ramus descendens anterior arteriae coronariae sinistrae, and slow iv lignocaine 8mg/kg is in case the ventricular fibrillation that may cause before the ligation is sewed up pericardium and thoracic wall subsequently.24h behind the heart infarction, Canis familiaris L. is put to death after pentobarbital sodium anesthesia, take out heart rapidly, excision trunk and fatty tissue, check the position of anterior descending branch ligation point, claim heavy whole-heartedly, excise right ventricle and left atrium then, stay interventricular septum and left atrium, claim to such an extent that left ventricle is heavy, from the apex of the heart and beginning and anterior descending branch vertical direction left ventricle is cut into the thick flesh sheet of 2-3mm, be dipped in dyeing 30min in the nitro tetrazolium blue solution (NBT), cut ischemic region cardiac muscular tissue and weigh, the calculating myocardium infarction size, that is: heart infarction scope=ischemic region weight/left ventricle is heavy by * 100%, the results are shown in Table 2.
The influence of table 2 pair qi-deficiency type Cor Canitis chamber infarction size
Annotate: compare with the normal saline group,
*P＜0.05,
*P＜0.01
Embodiment 2
Utilize the thrombosis method to measure to the thrombotic influence of qi-deficiency type rat.
Laboratory animal: the rat of body weight 300-400 grams, male and female are regardless of.(causing model of qi-asthenia according to document) by herbal pharmacology teaching and research room of Shenyang Pharmaceutical University
Experiment medicine: XUESAITONG PIAN (Kunming Medicine Group Stock Co., Ltd)
Pharmaceutical composition of the present invention
Experimental technique: get rat and be divided into the normal saline group, the XUESAITONG ZHUSHEYE group, pharmaceutical composition group of the present invention, the administration group is respectively at gastric infusion, the each 160mg effective site/kg of dosage, normal saline groups etc. are held inequality, administration every day 1 time, successive administration 3 days, administration the 3rd day with rat anesthesia (pentobarbital sodium 30-40mg/kg, ip), dorsal position is fixed, separate trachea, insert a plastic bushing, and separate right common carotid artery and left external jugular vein, put into a long silk thread of 6 centimetres in the stage casing of polyethylene tube, with heparin-saline solution, be full of polyethylene tube, after an end of polyethylene tube inserts left external jugular vein, inject anticoagulant heparin accurately by polyethylene tube, and then the other end of polyethylene tube inserted right common carotid artery, and open bulldog clamp, blood flow to polyethylene tube from right common carotid artery, return left external jugular vein, open blood flow Herba Clinopodii after 15 minutes takes out silk thread rapidly and weighs, and gross weight deducts silk thread weight and promptly gets thrombus weight.The animal wet weight of thrombus of blank group and administration group is carried out record, calculate, as shown in table 3:
The thrombus weight of each administration group of table 3
Annotate: compare with the normal saline group,
*P＜0.05,
*P＜0.01
Embodiment 3
Protective effect to the qi-deficiency type acute cerebral ischemia in rats
Laboratory animal: the SD rat, body weight (350 ± 47), male and female are regardless of.
Experiment medicine: XUESAITONG ZHUSHEYE (Kunming Medicine Group Stock Co., Ltd)
Pharmaceutical composition group of the present invention
Experimental technique: get rat and be divided into normal saline group, XUESAITONG ZHUSHEYE group, pharmaceutical composition group of the present invention, the administration group is respectively at intraperitoneal administration, the each 41mg effective site/kg of dosage, and normal saline groups etc. are held inequality, and administration began experiment in 2 hours.Acute imperfection cerebral ischemic model: rat pentobarbital sodium (40mg/kg) the ip anesthesia after the administration, the cervical region median incision, tracheal intubation is separated bilateral carotid, and dual ligation is also cut off, and 3h, 6h detect the variation of EEG after cerebral ischemia.Break end fast behind the 6h and get brain, change to detect brain water content and tectology.
The results are shown in Table 4:
The change of EEG: the change according to document ischemic stage EEG is divided into 4 grades, the I level by its amplitude decline degree: no change, amplitude are more than 75% of former level; II level: the slight inhibition, be 50%～75% of former level; The III level: moderate suppresses, and is 25%～50% of former level; The IV level: severe inhibition becomes 25% of the former level that is flat to.。
The protective effect of table 4 pair qi-deficiency type acute cerebral ischemia in rats
Annotate: compare with the normal saline group,
*P＜0.05,
*P＜0.01
Conclusion: show that by above pharmacological evaluation the present invention respectively organizes preparation the qi-deficiency type cardiovascular and cerebrovascular disease is had better pharmacological action.
Pharmaceutical composition of the present invention carries out the antitumor clinical experiment, discovery has favorable anti-tumor effect, tumor is dwindled 50% effective percentage and is reached more than 80%, positive control drug ad pro injection tumor is dwindled 50% effective percentage and is had only 60%, proves absolutely that pharmaceutical composition of the present invention has the effect of good antitumor pharmacology
Preparation embodiment
Embodiment 1
(1) raw medicinal material of the present invention's use is:
Radix Notoginseng 1000 grams, Radix Ginseng 1000 grams;
(2) preparation of Radix Notoginseng total arasaponins, Radix Ginseng total saponins: get Radix Notoginseng, Radix Ginseng, pulverize, put into the Chinese medicine multi-function extractor,, extract 4 times with 60% ethanol extraction 1 hour, extracting solution filters and merges, reclaim ethanol to the greatest extent, the ratio that extracting solution adds water to medical material and medicinal liquid is 1:1, leaves standstill, centrifugal, obtain supernatant;
(3) NKA type macroporous adsorptive resins on the supernatant is washed with distillation earlier, is 3 times of column volume with distilled water, water liquid discards, and reuse 55% ethanol elution, eluting ethanol are 2 times of column volume, eluent reclaims ethanol to most, and dry, pulverizing promptly gets Radix Notoginseng total arasaponins, Radix Ginseng total saponins 160 grams.
(4) preparation of preparation:
Get Radix Notoginseng total arasaponins, Radix Ginseng total saponins 160 grams, be prepared into 1000 bottles of 1000 bottles of 1000 bottles of 1000 bottles of 1000 of 10000 of 1000 bags of 1000 of 1000 in tablet or capsules or granules or drop pills or soft capsules or oral liquids or aqueous injection or infusion solutions or injectable powder.
Embodiment 2
(1) raw medicinal material of the present invention's use is:
Radix Notoginseng 3000 grams, Radix Ginseng 2000 grams;
(2) preparation of Radix Notoginseng total arasaponins, Radix Ginseng total saponins: get Radix Notoginseng, Radix Ginseng, pulverize, put into the Chinese medicine multi-function extractor,, extract 8 times with 70% ethanol extraction 3 hours, extracting solution filters and merges, reclaim ethanol to the greatest extent, the ratio that extracting solution adds water to medical material and medicinal liquid is 1:1, leaves standstill, centrifugal, obtain supernatant;
(3) AB-8 type macroporous adsorptive resins on the supernatant, earlier with the distillation washing, with distilled water 5 times of column volume, water liquid discards, reuse 75% ethanol elution, eluting ethanol are 6 times of column volume, and eluent reclaims ethanol to most, dry, pulverizing promptly get Radix Notoginseng total arasaponins, Radix Ginseng total saponins 440 grams.
(4) preparation of preparation:
The preparation of aqueous injection: get Radix Notoginseng total arasaponins, Radix Ginseng total saponins 440 grams, be prepared into 1000 bottles of 1000 bottles of 1000 bottles of 1000 bottles of 1000 of 10000 of 1000 bags of 1000 of 1000 in tablet or capsules or granules or drop pills or soft capsules or oral liquids or aqueous injection or infusion solutions or injectable powder.
Embodiment 3
(1) raw medicinal material of the present invention's use is:
Radix Notoginseng 1000 grams, Radix Ginseng 2000 grams
(2) preparation of Radix Notoginseng total arasaponins, Radix Ginseng total saponins: get Radix Notoginseng, Radix Ginseng, pulverize, put into the Chinese medicine multi-function extractor,, extract 4 times with 60% ethanol extraction 3 hours, extracting solution filters and merges, reclaim ethanol to the greatest extent, the ratio that extracting solution adds water to medical material and medicinal liquid is 1:1, leaves standstill, centrifugal, obtain supernatant;
(3) D101 type macroporous adsorptive resins on the supernatant, earlier with the distillation washing, with distilled water 3 times of column volume, water liquid discards, reuse 75% ethanol elution, eluting ethanol are 3 times of column volume, and eluent reclaims ethanol to most, dry, pulverizing promptly get Radix Notoginseng total arasaponins, Radix Ginseng total saponins 203 grams.
(4) preparation of preparation:
The preparation of aqueous injection: get Radix Notoginseng total arasaponins, Radix Ginseng total saponins 203 grams, be prepared into 1000 bottles of 1000 bottles of 1000 bottles of 1000 bottles of 1000 of 10000 of 1000 bags of 1000 of 1000 in tablet or capsules or granules or drop pills or soft capsules or oral liquids or aqueous injection or infusion solutions or injectable powder.
Embodiment 4
(1) raw medicinal material of the present invention's use is:
Radix Notoginseng 3000 grams, Radix Ginseng 1000 grams;
(2) preparation of Radix Notoginseng total arasaponins, Radix Ginseng total saponins: get Radix Notoginseng, Radix Ginseng, pulverize, put into the Chinese medicine multi-function extractor,, extract 8 times with 70% ethanol extraction 1 hour, extracting solution filters and merges, reclaim ethanol to the greatest extent, the ratio that extracting solution adds water to medical material and medicinal liquid is 1:1, leaves standstill, centrifugal, obtain supernatant;
(3) D101 type macroporous adsorptive resins on the supernatant, earlier with the distillation washing, with distilled water 4 times of column volume, water liquid discards, reuse 60% ethanol elution, eluting ethanol are 4 times of column volume, and eluent reclaims ethanol to most, dry, pulverizing promptly get Radix Notoginseng total arasaponins, Radix Ginseng total saponins 398 grams.
(4) preparation of preparation:
The preparation of aqueous injection: get Radix Notoginseng total arasaponins, Radix Ginseng total saponins 398 grams, be prepared into 1000 bottles of 1000 bottles of 1000 bottles of 1000 bottles of 1000 of 10000 of 1000 bags of 1000 of 1000 in tablet or capsules or granules or drop pills or soft capsules or oral liquids or aqueous injection or infusion solutions or injectable powder.
Embodiment 5
(1) raw medicinal material of the present invention's use is:
Radix Notoginseng 1500 grams, Radix Ginseng 1500 grams;
(2) preparation of Radix Notoginseng total arasaponins, Radix Ginseng total saponins: get Radix Notoginseng, Radix Ginseng, pulverize, put into the Chinese medicine multi-function extractor,, extract 6 times with 65% ethanol extraction 2 hours, extracting solution filters and merges, reclaim ethanol to the greatest extent, the ratio that extracting solution adds water to medical material and medicinal liquid is 1:1, leaves standstill, centrifugal, obtain supernatant;
(3) AB-8 type macroporous adsorptive resins on the supernatant, earlier with the distillation washing, with distilled water 4 times of column volume, water liquid discards, reuse 65% ethanol elution, eluting ethanol are 5 times of column volume, and eluent reclaims ethanol to most, dry, pulverizing promptly get Radix Notoginseng total arasaponins, Radix Ginseng total saponins 246 grams.
(4) preparation of preparation:
The preparation of aqueous injection: get Radix Notoginseng total arasaponins, Radix Ginseng total saponins 246 grams, be prepared into 1000 bottles of 1000 bottles of 1000 bottles of 1000 bottles of 1000 of 10000 of 1000 bags of 1000 of 1000 in tablet or capsules or granules or drop pills or soft capsules or oral liquids or aqueous injection or infusion solutions or injectable powder.
Embodiment 6
(1) raw medicinal material of the present invention's use is:
Radix Notoginseng 2000 grams, Radix Ginseng 1600 grams;
(2) preparation of Radix Notoginseng total arasaponins, Radix Ginseng total saponins: get Radix Notoginseng, Radix Ginseng, pulverize, put into the Chinese medicine multi-function extractor,, extract 7 times with 66% ethanol extraction 2.5 hours, extracting solution filters and merges, reclaim ethanol to the greatest extent, the ratio that extracting solution adds water to medical material and medicinal liquid is 1:1, leaves standstill, centrifugal, obtain supernatant;
(3) NKA type macroporous adsorptive resins on the supernatant is washed with distillation earlier, is 4 times of column volume with distilled water, water liquid discards, and reuse 70% ethanol elution, eluting ethanol are 5 times of column volume, eluent reclaims ethanol to most, and dry, pulverizing promptly gets Radix Notoginseng total arasaponins, Radix Ginseng total saponins 304 grams.
(4) preparation of preparation:
The preparation of aqueous injection: get Radix Notoginseng total arasaponins, Radix Ginseng total saponins 304 grams, be prepared into 1000 bottles of 1000 bottles of 1000 bottles of 1000 bottles of 1000 of 10000 of 1000 bags of 1000 of 1000 in tablet or capsules or granules or drop pills or soft capsules or oral liquids or aqueous injection or infusion solutions or injectable powder.
Embodiment 7
(1) raw medicinal material of the present invention's use is:
Radix Notoginseng 2500 grams, Radix Ginseng 1200 grams;
(2) preparation of Radix Notoginseng total arasaponins, Radix Ginseng total saponins: get Radix Notoginseng, Radix Ginseng, pulverize, put into the Chinese medicine multi-function extractor,, extract 6 times with 65% ethanol extraction 1.5 hours, extracting solution filters and merges, reclaim ethanol to the greatest extent, the ratio that extracting solution adds water to medical material and medicinal liquid is 1:1, leaves standstill, centrifugal, obtain supernatant;
(3) D101 type macroporous adsorptive resins on the supernatant, earlier with the distillation washing, with distilled water 5 times of column volume, water liquid discards, reuse 60% ethanol elution, eluting ethanol are 6 times of column volume, and eluent reclaims ethanol to most, dry, pulverizing promptly get Radix Notoginseng total arasaponins, Radix Ginseng total saponins 388 grams.
(4) preparation of preparation:
The preparation of aqueous injection: get Radix Notoginseng total arasaponins, Radix Ginseng total saponins 388 grams, be prepared into 1000 bottles of 1000 bottles of 1000 bottles of 1000 bottles of 1000 of 10000 of 1000 bags of 1000 of 1000 in tablet or capsules or granules or drop pills or soft capsules or oral liquids or aqueous injection or infusion solutions or injectable powder.
Annotate: Radix Ginseng raw material packet of the present invention is drawn together SHANSHEN, Park Ginseng, Radix Ginseng Rubra, Folium Ginseng.
Claims (3)
1, a kind of pharmaceutical composition that contains Radix Notoginseng, Radix Ginseng is characterized in that this pharmaceutical composition is by Radix Notoginseng 1-3 weight portions, and Radix Ginseng 1-2 weight portions are formed.
2, a kind of pharmaceutical composition that contains Radix Notoginseng, Radix Ginseng according to claim 1, it is characterized in that the preparation of pharmaceutical compositions method: get Radix Notoginseng, Radix Ginseng, pulverize, put into the Chinese medicine multi-function extractor, added 6-10 times of water extraction 1-3 hours, extract 2-5 times, extracting solution filters and merges, filter, the ratio that filtrate is concentrated into medical material and medicinal liquid is 1:1, leaves standstill, centrifugal, obtain supernatant, supernatant adds ethanol, and making solution contain the alcohol amount is 50%-80%, left standstill 24-36 hours, supernatant reclaims ethanol to most, and it is standby to obtain concentrated solution, the precipitation drying for standby; Getting macroporous adsorptive resins on the above-mentioned concentrated solution, wash with distillation earlier, is 3-5 times of column volume with distilled water, water liquid discards, and reuse 55%-75% ethanol elution, eluting ethanol are 2-6 times of column volume, eluent reclaims ethanol to most, and dry, pulverizing is standby; Get above-mentioned drying precipitated, be dissolved in water fully, with 0.1 μ m filter element filtering, filtrate is that 8000-10000 hollow fiber column carries out ultrafiltration with the intercepting molecular weight, and each ultrafiltration is during to original volume 1/2-1/3, add water to original volume, ultrafiltration 3-5 times is concentrated to pol when being 1%-4%, drying for the last time, add the dry thing of macroporous adsorptive resins ethanol elution, obtain Radix Notoginseng, Radix Ginseng extract.
3, the preparation of preparation of pharmaceutical compositions according to claim 1 the treatment tumor disease aspect in application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007103038602A CN101468053A (en) | 2007-12-26 | 2007-12-26 | Pharmaceutical composition containing notoginseng and ginseng as well as preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007103038602A CN101468053A (en) | 2007-12-26 | 2007-12-26 | Pharmaceutical composition containing notoginseng and ginseng as well as preparation and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101468053A true CN101468053A (en) | 2009-07-01 |
Family
ID=40826015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007103038602A Pending CN101468053A (en) | 2007-12-26 | 2007-12-26 | Pharmaceutical composition containing notoginseng and ginseng as well as preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101468053A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953865B (en) * | 2009-07-16 | 2012-03-21 | 赤峰天奇制药有限责任公司 | Chinese medicinal composition for treating ischemic heart diseases and preparation method thereof |
| CN112587558A (en) * | 2020-11-06 | 2021-04-02 | 邓乃哲 | Health-preserving health-care traditional Chinese medicine composition, preparation and application thereof |
| CN115463187A (en) * | 2018-08-24 | 2022-12-13 | 昆明思多尔生物科技有限公司 | Application of anticancer composition in preparation of medicine for treating cancer |
-
2007
- 2007-12-26 CN CNA2007103038602A patent/CN101468053A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953865B (en) * | 2009-07-16 | 2012-03-21 | 赤峰天奇制药有限责任公司 | Chinese medicinal composition for treating ischemic heart diseases and preparation method thereof |
| CN115463187A (en) * | 2018-08-24 | 2022-12-13 | 昆明思多尔生物科技有限公司 | Application of anticancer composition in preparation of medicine for treating cancer |
| CN112587558A (en) * | 2020-11-06 | 2021-04-02 | 邓乃哲 | Health-preserving health-care traditional Chinese medicine composition, preparation and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101375990B (en) | Composition for treating cardiovascular disease and preparation thereof | |
| CN1931236B (en) | Medicine composition of red sage and rhodiola root | |
| CN1923241B (en) | Medicine composition containing epimedium extract, uncaria extract, and gastrodine, and its preparation and use | |
| CN101468053A (en) | Pharmaceutical composition containing notoginseng and ginseng as well as preparation and application thereof | |
| CN103837609A (en) | Pulse-activating injection and preparation method thereof | |
| CN1981849B (en) | Production and use for milkvetch root Shengmai injection | |
| CN101152285B (en) | Pharmaceutical composition of snakegourd fruit and whitethorn leaf | |
| CN1931233B (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
| CN101292987B (en) | Pharmaceutical combination | |
| CN101623437A (en) | Pulse activating preparation for injection and its preparation method | |
| CN101293009A (en) | Pharmaceutical composition | |
| CN101049355B (en) | Composition of medication prepared from safflower and leaves of hawthorn | |
| CN100563682C (en) | A kind of pharmaceutical composition of making by Folium Crataegi and Radix Rhodiolae and preparation method thereof | |
| CN101199568A (en) | Medicament compound for treating cardiovascular disease and preparing method thereof | |
| CN100448457C (en) | Effective position of pilose asiabell root, preparation, medication use and preparation method | |
| CN1468860A (en) | Manyprickle acanthopanax general saponin extractive and its medicinal composition | |
| CN1899352B (en) | Chinese medicine effective part composition for supplementing qi and recovering pulse | |
| CN101019824B (en) | Preparation method of oral medicine composition containing salvianolic acid | |
| CN101019878B (en) | Injection medicine composite containing salvianolic acid A and its preparation | |
| CN100502937C (en) | Chinese medicine composition for treating cardiovascular disease and its preparing method | |
| CN100484543C (en) | Medicament composition for treating hepatitis, prepartion method and use | |
| CN101167784A (en) | Medicinal composition for cardiovascular and cerebrovascular diseases | |
| CN102319401A (en) | A kind of Chinese medicine composition that is used for benefiting QI for activating blood circulation, spleen invigorating collateral dredging and preparation method thereof | |
| CN101190253B (en) | Medicinal composition containing mongolian snakegourd and notoginseng | |
| CN100430076C (en) | Medicine composition for treating hyperlipemia and coronary disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090701 |